Tocilizumab for treating severe COVID-19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series

Tocilizumab for treating severe COVID-19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series

© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. Three patients diagnosed with severe COVID-19 pneumonia received treatment with hydroxychloroquine combined with lopinavir, ritonavir, and favipiravir. Two patients diagnosed early, received tocilizumab when the pneu...

Full description

Saved in:
Bibliographic Details
Main Authors: Manoon Surabotsophon, Yingyot Klai-On, Vipa Thanachartwet, Sirote Khunapornphairote, Supat Chamnanchanunt, Theerapat Racharak, Wannada Laisuan, Duangjai Sahassananda, Samlee Hapunna, Somjit Jinapuk, Suthee Leelasetakul, Varunee Desakorn
Other Authors: Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Format: Article
Published: 2020
Subjects:
Medicine
Online Access:https://repository.li.mahidol.ac.th/handle/123456789/60534
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Mahidol University

Internet

https://repository.li.mahidol.ac.th/handle/123456789/60534

Similar Items